Performance Status and Early Death in Advanced Soft Tissue Sarcoma
Author Information
Author(s): Penel N, Glabbeke M V, Mathoulin-Pelissier S, Judson I, Sleijfer S, Bui B, Schoffski P, Ouali M, Marreaud S, Brouste V, Duhamel A, Hohenberger P, Blay J-Y
Primary Institution: European Organisation for Research and Treatment of Cancer
Hypothesis
Is performance status a significant risk factor for early death among patients with advanced soft tissue sarcoma?
Conclusion
Performance status is a crucial factor in predicting early death in patients with advanced soft tissue sarcoma and should guide treatment decisions.
Supporting Evidence
- The 90-day mortality rate was 8.6% in the STBSG cohort and 4.5% in the FSG cohort.
- Performance status was identified as the most powerful prognostic factor for early death.
- Logistic regression analysis showed significant odds ratios for performance status and presence of liver metastasis.
Takeaway
Doctors found that how well a patient is doing can help predict if they might die soon after starting treatment for a type of cancer called soft tissue sarcoma.
Methodology
The study used logistic regression and probability tree analysis on data from two cohorts of patients with advanced soft tissue sarcoma.
Potential Biases
Potential biases due to overestimation of life expectancy and performance status by physicians.
Limitations
The study is retrospective, and some prognostic factors may not have been available for all patients.
Participant Demographics
The study included 3002 patients with advanced soft tissue sarcoma, with a mix of genders and performance statuses.
Statistical Information
P-Value
p<0.0001
Confidence Interval
95% CI: 7.6–9.6
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website